MX373319B - Derivados de hexahidro-[1-4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor. - Google Patents
Derivados de hexahidro-[1-4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor.Info
- Publication number
- MX373319B MX373319B MX2017013902A MX2017013902A MX373319B MX 373319 B MX373319 B MX 373319B MX 2017013902 A MX2017013902 A MX 2017013902A MX 2017013902 A MX2017013902 A MX 2017013902A MX 373319 B MX373319 B MX 373319B
- Authority
- MX
- Mexico
- Prior art keywords
- tobacco
- individual attempting
- addiction
- smoking
- disorders
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 title 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 title 1
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 241000208125 Nicotiana Species 0.000 abstract 5
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 4
- 229960002715 nicotine Drugs 0.000 abstract 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 4
- 230000000391 smoking effect Effects 0.000 abstract 4
- 230000004584 weight gain Effects 0.000 abstract 4
- 235000019786 weight gain Nutrition 0.000 abstract 4
- 206010012335 Dependence Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000005586 smoking cessation Effects 0.000 abstract 3
- 208000016285 Movement disease Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 206010057342 Onychophagia Diseases 0.000 abstract 2
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 2
- 230000000561 anti-psychotic effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 230000000153 supplemental effect Effects 0.000 abstract 2
- 235000019505 tobacco product Nutrition 0.000 abstract 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000001613 Gambling Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000030990 Impulse-control disease Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 206010057852 Nicotine dependence Diseases 0.000 abstract 1
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 206010034158 Pathological gambling Diseases 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 208000021017 Weight Gain Diseases 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 230000036186 satiety Effects 0.000 abstract 1
- 235000019627 satiety Nutrition 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 230000007958 sleep Effects 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 230000037322 slow-wave sleep Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000037221 weight management Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153082P | 2015-04-27 | 2015-04-27 | |
| PCT/US2016/029308 WO2016176177A1 (en) | 2015-04-27 | 2016-04-26 | 5-ht2c receptor agonists and compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017013902A MX2017013902A (es) | 2018-03-16 |
| MX373319B true MX373319B (es) | 2020-06-13 |
Family
ID=55949111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013902A MX373319B (es) | 2015-04-27 | 2016-04-26 | Derivados de hexahidro-[1-4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor. |
| MX2020005898A MX2020005898A (es) | 2015-04-27 | 2017-10-27 | Derivados de hexahidro-[1,4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005898A MX2020005898A (es) | 2015-04-27 | 2017-10-27 | Derivados de hexahidro-[1,4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10392390B2 (OSRAM) |
| EP (1) | EP3288946B1 (OSRAM) |
| JP (1) | JP6675688B2 (OSRAM) |
| KR (1) | KR102275505B1 (OSRAM) |
| CN (1) | CN107873030B (OSRAM) |
| AU (1) | AU2016255009B2 (OSRAM) |
| BR (1) | BR112017023088B1 (OSRAM) |
| CA (1) | CA3002544C (OSRAM) |
| DK (1) | DK3288946T3 (OSRAM) |
| EA (1) | EA034446B1 (OSRAM) |
| ES (1) | ES2757922T3 (OSRAM) |
| HK (1) | HK1244005B (OSRAM) |
| HR (1) | HRP20192044T1 (OSRAM) |
| HU (1) | HUE047169T2 (OSRAM) |
| IL (1) | IL255171A0 (OSRAM) |
| MX (2) | MX373319B (OSRAM) |
| PT (1) | PT3288946T (OSRAM) |
| WO (1) | WO2016176177A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
| PT3746126T (pt) | 2018-01-30 | 2024-10-21 | Apnimed Inc Delaware | Métodos e composições para o tratamento de apneia do sono ou roncopatia simples |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| PH12021551850A1 (en) * | 2019-02-08 | 2022-05-11 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| JP2022529353A (ja) | 2019-04-17 | 2022-06-21 | コンパス パスファインダー リミテッド | 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法 |
| US12205686B2 (en) * | 2020-02-27 | 2025-01-21 | The Cleveland Clinic Foundation | Identifying patients for intensive hyperglycemia management |
| US20250073206A1 (en) * | 2021-10-29 | 2025-03-06 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
| CA3240561A1 (en) * | 2021-12-10 | 2023-06-15 | GATC Health Corp | Methods of treating addiction and neurological disorders |
| EP4489761A1 (en) | 2022-03-10 | 2025-01-15 | Arena Pharmaceuticals, Inc. | Methods of treatment |
| CN114965250B (zh) * | 2022-05-19 | 2025-02-14 | 道生天合材料科技(上海)股份有限公司 | 胶粘剂储存期的预测方法 |
| WO2023225773A1 (en) * | 2022-05-23 | 2023-11-30 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
| JP2025540125A (ja) * | 2022-12-02 | 2025-12-11 | アリーナ ファーマシューティカルズ，インコーポレイテッド | 治療の方法 |
| EP4665319A1 (en) * | 2023-02-17 | 2025-12-24 | Caamtech, Inc. | 2-(2,5-diethoxy-4-(ethylthio)phenyl)ethane-1-aminium chloride |
| WO2024182807A2 (en) * | 2023-03-02 | 2024-09-06 | Alexander Shulgin Research Institute, Inc. | Phenylalkylamine prodrugs |
| WO2025080932A1 (en) * | 2023-10-11 | 2025-04-17 | University Of Padova | Methods of treatment with psilocybin and psilocin derivatives |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3642822A (en) * | 1969-11-03 | 1972-02-15 | Upjohn Co | Hexahydropyrrolobenzodiazepines |
| US4597961A (en) | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
| US4920989A (en) | 1985-04-25 | 1990-05-01 | Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
| IL86170A (en) | 1987-05-01 | 1992-12-01 | Elan Transdermal Ltd | Preparations and compositions comprising nicotine for percutaneous administration |
| US5004610A (en) | 1988-06-14 | 1991-04-02 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
| AU1919592A (en) | 1991-04-16 | 1992-11-17 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
| ES2230382T3 (es) * | 2000-11-03 | 2005-05-01 | Wyeth | Ciclopental(b)(1,4)diazpino(6,7,1-hi)indoles como antagonistas de 5ht2c. |
| WO2002036596A2 (en) | 2000-11-03 | 2002-05-10 | Wyeth | CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES |
| WO2003086303A2 (en) | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| TW200307540A (en) * | 2002-04-25 | 2003-12-16 | Wyeth Corp | [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents |
| JP4782003B2 (ja) * | 2003-06-17 | 2011-09-28 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５ｈｔ２ｃレセプター関連疾患の処置に有用なベンズアゼピン誘導体 |
| TW200806321A (en) * | 2006-03-24 | 2008-02-01 | Wyeth Corp | New therapeutic combinations for the treatment or prevention of psychotic disorders |
| WO2013133325A1 (ja) * | 2012-03-06 | 2013-09-12 | 武田薬品工業株式会社 | 三環性化合物 |
| HK1212684A1 (zh) * | 2012-09-14 | 2016-06-17 | AbbVie Deutschland GmbH & Co. KG | 三環喹啉和喹喔啉衍生物 |
| WO2015066344A1 (en) * | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
-
2016
- 2016-04-26 KR KR1020177033892A patent/KR102275505B1/ko active Active
- 2016-04-26 PT PT167213206T patent/PT3288946T/pt unknown
- 2016-04-26 HK HK18103485.6A patent/HK1244005B/en unknown
- 2016-04-26 JP JP2017555768A patent/JP6675688B2/ja active Active
- 2016-04-26 MX MX2017013902A patent/MX373319B/es active IP Right Grant
- 2016-04-26 WO PCT/US2016/029308 patent/WO2016176177A1/en not_active Ceased
- 2016-04-26 EP EP16721320.6A patent/EP3288946B1/en active Active
- 2016-04-26 US US15/567,116 patent/US10392390B2/en active Active
- 2016-04-26 HU HUE16721320A patent/HUE047169T2/hu unknown
- 2016-04-26 AU AU2016255009A patent/AU2016255009B2/en active Active
- 2016-04-26 BR BR112017023088-7A patent/BR112017023088B1/pt active IP Right Grant
- 2016-04-26 EA EA201792356A patent/EA034446B1/ru not_active IP Right Cessation
- 2016-04-26 DK DK16721320T patent/DK3288946T3/da active
- 2016-04-26 HR HRP20192044TT patent/HRP20192044T1/hr unknown
- 2016-04-26 ES ES16721320T patent/ES2757922T3/es active Active
- 2016-04-26 CN CN201680037275.XA patent/CN107873030B/zh active Active
- 2016-04-26 CA CA3002544A patent/CA3002544C/en active Active
-
2017
- 2017-10-22 IL IL255171A patent/IL255171A0/en active IP Right Grant
- 2017-10-27 MX MX2020005898A patent/MX2020005898A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20192044T1 (hr) | 2020-02-07 |
| MX2017013902A (es) | 2018-03-16 |
| CN107873030B (zh) | 2021-03-19 |
| BR112017023088A2 (pt) | 2018-07-10 |
| CA3002544C (en) | 2024-03-05 |
| HUE047169T2 (hu) | 2020-04-28 |
| MX2020005898A (es) | 2020-08-13 |
| EA201792356A1 (ru) | 2018-05-31 |
| WO2016176177A1 (en) | 2016-11-03 |
| CN107873030A (zh) | 2018-04-03 |
| IL255171A0 (en) | 2017-12-31 |
| DK3288946T3 (da) | 2019-11-25 |
| JP6675688B2 (ja) | 2020-04-01 |
| CA3002544A1 (en) | 2016-11-03 |
| NZ737412A (en) | 2021-06-25 |
| EP3288946B1 (en) | 2019-08-21 |
| KR20170140317A (ko) | 2017-12-20 |
| KR102275505B1 (ko) | 2021-07-08 |
| US20180186797A1 (en) | 2018-07-05 |
| PT3288946T (pt) | 2019-11-27 |
| EA034446B1 (ru) | 2020-02-10 |
| AU2016255009A1 (en) | 2017-12-14 |
| HK1244005B (en) | 2020-04-17 |
| EP3288946A1 (en) | 2018-03-07 |
| JP2018519251A (ja) | 2018-07-19 |
| US10392390B2 (en) | 2019-08-27 |
| AU2016255009B2 (en) | 2020-10-08 |
| BR112017023088B1 (pt) | 2023-10-03 |
| ES2757922T3 (es) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX373319B (es) | Derivados de hexahidro-[1-4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor. | |
| MX375045B (es) | Agonistas del receptor 5-ht2c y composiciones y metodos de uso. | |
| MX391442B (es) | Agonistas y composiciones del receptor 5-ht2c y métodos de uso. | |
| ECSP11011250A (es) | [1, 2, 4] triazolo [1, 5 -a] piridinas como inhibidores de cinasa | |
| EA201201201A1 (ru) | Новые ингибиторы rock | |
| EA201190303A1 (ru) | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ | |
| EA201891374A1 (ru) | Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение | |
| EA201591290A3 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| CR8928A (es) | Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas | |
| MY172308A (en) | Bicyclic pyrazinone derivatives | |
| TN2011000319A1 (en) | Substituted quinazoline compounds | |
| NZ605022A (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
| TN2016000511A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| MX2020010908A (es) | Composiciones infundidas con compuestos de nicotina y metodos de uso de las mismas. | |
| CO6361991A2 (es) | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos. | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| EA201690880A1 (ru) | Тетрациклические ингибиторы аутотаксина | |
| PH12019502315A1 (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
| MX2016008042A (es) | Derivados de imidazopirazinona. | |
| AR098271A1 (es) | Agonistas del receptor 5-ht₂c | |
| MX2018011283A (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer. | |
| PE20211268A1 (es) | Proceso para preparar el benzotiofen-2-il boronato | |
| Ossemann | Recurrence of cluster headache with pramipexole. | |
| MX2018013324A (es) | Métodos y composiciones para el tratamiento del síndrome de rett. | |
| DOP2015000029A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |